Global Chemotherapy-induced Neutropenia Therapeutics Market 2018-2022
|出版商||TechNavio (Infiniti Research Ltd.)||商品編碼||650398|
|出版日期||內容資訊||英文 102 Pages
|化療誘發性嗜中性白血球低下症治療藥的全球市場:2018年∼2022年 Global Chemotherapy-induced Neutropenia Therapeutics Market 2018-2022|
|出版日期: 2018年05月15日||內容資訊: 英文 102 Pages||
Neutrophils are immunity-inducing white blood cells. Reduction in its number causes neutropenia. Chemotherapy-induced neutropenia occurring during treatment increases patient's risk of infection and disrupts cancer treatment.
Technavio's analysts forecast the Global Chemotherapy-Induced Neutropenia Therapeutics Market to grow at a CAGR of 5.52% during the period 2018-2022.
The report covers the present scenario and the growth prospects of the global chemotherapy-induced neutropenia therapeutics market. To calculate the market size, the report considers the revenue generated from the adoption of CIN treatment.
The market is divided into the following segments based on geography:
Technavio's report, Global Chemotherapy-induced Neutropenia Therapeutics Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.